The limited efficacy of R-PRRT as compared to initial PRRT might be explained by the administration of lower cumulative activity (i.e., generally half of the initial PRRT dosage) [51], the increase in tumor bulk at baseline before R-PRRT and potential changes in the tumor biology, such as a longitudinal increase in Ki-67. The gene discussed is MKI67; the disease is neoplasm.